CN104825702A - Composition capable of reducing fat and supplying nutrients and preparation method thereof - Google Patents
Composition capable of reducing fat and supplying nutrients and preparation method thereof Download PDFInfo
- Publication number
- CN104825702A CN104825702A CN201510228700.0A CN201510228700A CN104825702A CN 104825702 A CN104825702 A CN 104825702A CN 201510228700 A CN201510228700 A CN 201510228700A CN 104825702 A CN104825702 A CN 104825702A
- Authority
- CN
- China
- Prior art keywords
- dextrin
- rhizoma amorphophalli
- preparation
- amorphophalli powder
- solid preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Abstract
The invention relates to a composition capable of reducing fat and supplying nutrients and a preparation method thereof. The composition is composed of the following raw materials in parts by weight: 1 to 10 parts of konjak powder and 1 part of dextrin. According to the formula, a synergetic effect is generated; the composition can be made into tablets and particles, is capable of supplying nutrients continuously, and can supply nutrients that konjak powder does not contain.
Description
Technical field
The present invention relates to a kind of composition and method of making the same with fat-reducing and extra-nutrition effect, belong to medicine or technical field of health care food.
Background technology
21 century, obesity has become one of most important public health challenge.Fat closely related with metabolic syndrome (cardiovascular risk factors comprises hypertension, fat metabolic disturbance and insulin resistance), and can the life-span be reduced.According to estimates, have the American of 2/3 overweight or fat, in addition, along with developing country more and more adopts western diet and life style, bariatric patients's quantity will increase further.Estimate according to World Health Organization (WHO), in global range, Overweight and obesity crowd is more than 1,400,000,000.
Current multiple appetrol are quit listing, and doctor's difficulty has more therapeutic choice, and expert claims, the body weight of lasting reduction at least 5%, can reduce obesity and the cardiovascular disease relevant to obesity and diabetes risk.According to the guidance that regulator delivers, reduce 5% minimum standards of just losing weight of body weight, clinician and patient then have higher expectation, and they wish that fat-reducing effect is more obvious, namely at least reduce 10% of body weight.Commercially can the moderate medicine of curative effect in, because its tolerance is poor, safety is low, lack the reasons such as new therapy, inhibit the market development of obesity treatment drugs in itself.And the exploitation of disturbance to this market and new drug of quitting listing one after another of appetrol in recent years makes the matter worse especially.The subject matter of appetrol is its long-term safety.In past 40 years, 5 kinds of appetrol are withdrawn from the market because of potential safety hazard.Wherein, foremost two kinds of medicines are the Pondimin(fenfluramine of Wyeth's (being purchased by Pfizer)) and Redux(dexfenfluramine) withdrew from the market in 1997 years.These two kinds of medicines are found to increase valve disorder risk, and listing is only just withdrawn from the market for 1 year.The appetrol of quitting listing recently have the Meridia/Reductil(sibutramine of Abbott Laboratories), quit listing in 2010 due to cardiovascular disease may be caused; The Mediator(benfluorex of Servier company), owing to quitting listing in 2009 by cardiac trigger valvular heart disease; The Acomplia(Rimonabant of Sai Nuofei), quit listing in 2008 due to depression or suicidal idea may be caused.Most popular phentermine, belongs to the derivant of amphetamines, recent decades because of its cheap but not evident in efficacy or safe and reliable and use.Other conventional fat reduction therapy medicines are lipase inhibitor orlistat (Xenical on market and nonprescription drugs Alli), because orlistat often can cause gastrointestinal upset (as fecal incontinence or oiliness stool), also limit it and use further.But, along with sibutramine quitting listing in Europe, orlistat has become the medicine that this area uniquely may be used for losing weight.
In China market, in January, 2009, due to serious adverse reactions such as meeting cardiac trigger infringements, SFDA requires in China, forbids production and sales and uses fenfluramine hydrochloride tablets and raw material thereof.On October 30th, 2010, SFDA gives notice, and determine to stop sibutramine preparation and raw material in the producing and selling of China and use, the medicine of list marketing, is responsible for recalling destruction by manufacturing enterprise.This paper notifies, terminated the sales histories reaching 10 years with " Sibutramine Hydrochloride " the sibutramine series appetrol that are representative in China.
Below be all chemical drugs, life-time service more or less has untoward reaction or toxic and side effects, and some side effect is also very large, although compound Chinese medicinal preparation untoward reaction is less, general validity is poor.So it is few to find untoward reaction, safety, but eutherapeutic natural product is the problem needing solution badly.
Summary of the invention
The object of the present invention is to provide a kind of newly there is fat-reducing and the compositions of extra-nutrition effect, said composition fat-reducing instant effect, good effect and little to person side effect.
Another object of the present invention is to provide a kind of preparation method of above-mentioned composition.
In order to realize foregoing invention object, the invention provides following technical scheme:
Having a compositions for fat-reducing and extra-nutrition effect, is be made up of the raw material of following weight: Rhizoma amorphophalli powder 1 ~ 10 part, 1 part, dextrin.
Preferably, in above-mentioned raw materials proportioning, Rhizoma amorphophalli powder 2 ~ 8 parts, 1 part, dextrin.
Preferred, in above-mentioned raw materials proportioning, Rhizoma amorphophalli powder 5 parts, 1 part, dextrin.
In above-mentioned composition, dextrin is starch when being subject to heating, acid or diastatic action and issuing solution estranged and hydrolysis, and first macromolecular starch is transformed into micromolecular intermediate material.Preferred maltodextrin.
Dosage form described in above-mentioned composition is solid preparation; Can be preferably in tablet, granule, pressed candy etc. any one.
The preparation method of above-mentioned composition is: Rhizoma amorphophalli powder and the dextrin of getting described proportioning, and mix homogeneously, makes various solid preparation.
Also can add pharmaceutically acceptable carrier or/and adjuvant making in above-mentioned solid preparation process, but not add liquid adhesive.
In above-mentioned raw materials: the extraction of substance containing glucomannoglycan (KGM) that Rhizoma amorphophalli powder general reference is extracted from Rhizoma amorphophalli.Have the materials such as Rhizoma amorphophalli powder, konjaku powder, Rhizoma amorphophalli fine powder, Rhizoma amorphophalli fine powder, Rhizoma amorphophalli extract, Rhizoma amorphophalli micropowder, Konjac glucomannan, glucomannoglycan in the market, these are all included within the Rhizoma amorphophalli powder category of indication of the present invention.
The instructions of taking of product of the present invention is directly pour in mouth by solid preparation, use mixing in water for oral taking.
compared with prior art, beneficial effect of the present invention: compositions of the present invention is made up of Rhizoma amorphophalli powder, dextrin 2 kinds of raw materials, there is following distinguishing feature: after (1) this product introduction gastric, after contained Rhizoma amorphophalli powder absorbs moisture content under the environment of water, its volume is inflatable to about self 100 times, occupy gastric volume, thus make eater produce satiety, reduce the absorption of food total amount, reach the effect reducing energy intake and then fat-reducing; (2) in compositions, contained dextrin is the incomplete hydrolysate of starch, enter after in body, glucose can be hydrolyzed to further, compatibility together with Rhizoma amorphophalli powder, owing to forming gelling material after Rhizoma amorphophalli powder chance water, therefore dextrin can be made slowly to be hydrolyzed, nutrition slow releasing wherein, slowly to absorb, continue to supplement partial heat content of human body, be unlikely to the malnutrition causing food total amount Deficiency of Intake to cause, be particularly suitable for diabetic to take, significantly can reduce post-prandial glycemia; (3) the more important thing is: because dextrin has certain viscosity, itself and Rhizoma amorphophalli powder are combined when making solid preparation, also serve excellent adhesive effect, even do not need to add other adjuvants and liquid adhesive also can make solid preparation.So Rhizoma amorphophalli powder, dextrin compatibility use, and are not simple combinations, both respective advantage had been taken into full account, improve for weak point again, make curative effect compared with common konjac compositions product, there is apparent synergistic function, not only be beneficial to and make sheet and granule, and sustainablely provide nutrition, make up the undernutrition of Rhizoma amorphophalli powder, embody multi-efficiency, serve rapid-action, eutherapeutic effect, and without any side effects to patient body.
Detailed description of the invention
Below in conjunction with test example and detailed description of the invention, the present invention is described in further detail.But this should be interpreted as that the scope of the above-mentioned theme of the present invention is only limitted to following embodiment, all technology realized based on content of the present invention all belong to scope of the present invention.
Detailed description of the invention
Below in conjunction with detailed description of the invention, the present invention is described in further detail.
Embodiment 1-5, is grouped into according to one-tenth each in following table 1 and weight proportion makes corresponding composition solid preparation.
Table 1(unit: part)
| Rhizoma amorphophalli powder | Dextrin | Dosage form | |
| Embodiment 1 | 1 | 1 | Tablet |
| Embodiment 2 | 2 | 1 | Pressed candy |
| Embodiment 3 | 5 | 1 | Granule |
| Embodiment 4 | 8 | 1 | Tablet |
| Embodiment 5 | 10 | 1 | Granule |
| Comparative example 1 | 10 | 0 | Powder |
| Comparative example 2 | 0 | 1 | Powder |
Each embodiment is all obtained by following preparation method above:
Get the Rhizoma amorphophalli powder of described proportioning, dextrin, make corresponding solid preparation.
The compositions that inventor gets above-described embodiment 1-5 gained carries out curative effect on obesity clinical observation.For the ease of comparing the synergistic function between two kinds of raw materials, individually with two kinds of raw materials in contrast, because raw material combines, cannot solid preparation be made, seeing the comparative example 1 and 2 in above-mentioned table 1.
Methods of clinical observation and result as follows:
1, crowd is observed:
Select Body Mass Index BMI(body weight (kilogram)/height (rice
2)) >30(is fat more than 30) and crowd 270 example, be divided into 9 experimental grouies, each experimental group 30 people.
2, instructions of taking:
1st group to the 5th group: the product taken is corresponding embodiment 1 to embodiment 5 respectively, and dose is each 5g, pours product into oral cavity when taking, and takes after mixing it with water with 500ml warm water, every day Chinese meal and dinner within first 5 minutes, respectively take once, appetite does not control as usual.
Comparative example 1 and comparative example 2: the samely take mode.
6th group: blank group, do not take any product, appetite does not control as usual.
3, efficacy evaluation:
Weigh before taking, weigh after taking 30 days again, the weight that 2 times are reduced using front and back, as evaluation index, calculates the meansigma methods often organizing crowd's loss of weight, and evaluates often group performance status and mouthfeel.
4, therapeutic effect is shown in following table 2:
Table 2
| Group | Number of cases | Meansigma methods of losing weight (kg) | Muscle power, starvation | Mouthfeel |
| 1st group | 30 | 5.6 *** | Very well, not hungry | Good |
| 2nd group | 30 | 5.7 *** | Very well, not hungry | Good |
| 3rd group | 30 | 5.9 *** | Very well, not hungry | Good |
| 4th group | 30 | 5.8 *** | Good, not hungry | Good |
| 5th group | 30 | 5.9 *** | Good, not hungry | Good |
| 6th group | 30 | 0.1 | Very well, not hungry | - |
| Comparative example 1 | 30 | 5.3 ※※※ | Muscle power is not good, not hungry | Very poor |
| Comparative example 2 | 30 | 0.1 | Good, very hungry | Difference |
In table 2, (1) 1-5 group: compare with comparative example 2,
* *p < 0.01; (2) comparative example 1: compare with the 6th group,
※ ※ ※p < 0.01.
Learnt by statistical data in table 2, take the 1-5 group experimenter of product of the present invention, take 30 days continuously, fat-reducing effect is best, and not hungry, and p < 0.01, has significant difference compared with comparative example 2, especially better with the 3rd group of effect.Comparative example 1, compared with the 6th group (blank group), p < 0.01, has significant difference, also effective in cure, but muscle power is poor; Illustrate that Rhizoma amorphophalli powder, dextrin compatibility result of use are better, not only lose weight, also significantly improve performance status.Rhizoma amorphophalli powder discord dextrin combination in addition, single component cannot make solid preparation, then fishlike smell is very heavy, and mouthfeel is very poor, almost cannot adhere to for a long time taking.
Claims (8)
1. there is a compositions for fat-reducing and extra-nutrition effect, it is characterized in that: it is made up of the raw material of following weight: Rhizoma amorphophalli powder 1 ~ 10 part, 1 part, dextrin.
2. compositions according to claim 1, is characterized in that, the weight of described raw material is: Rhizoma amorphophalli powder 2 ~ 8 parts, 1 part, dextrin.
3. compositions according to claim 1, is characterized in that, the weight of described raw material is: Rhizoma amorphophalli powder 5 parts, 1 part, dextrin.
4. compositions according to claim 1, is characterized in that: described dextrin is maltodextrin.
5. compositions according to claim 1, is characterized in that: described dosage form is solid preparation.
6. compositions according to claim 5, is characterized in that: described solid preparation is any one in tablet, granule, pressed candy.
7. a preparation method for compositions according to claim 1, is characterized in that: Rhizoma amorphophalli powder and the dextrin of getting described proportioning, and mix homogeneously, makes various solid preparation.
8. method according to claim 7, is characterized in that: make in the process of solid preparation and do not add liquid adhesive.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510228700.0A CN104825702A (en) | 2015-05-07 | 2015-05-07 | Composition capable of reducing fat and supplying nutrients and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510228700.0A CN104825702A (en) | 2015-05-07 | 2015-05-07 | Composition capable of reducing fat and supplying nutrients and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN104825702A true CN104825702A (en) | 2015-08-12 |
Family
ID=53804151
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510228700.0A Pending CN104825702A (en) | 2015-05-07 | 2015-05-07 | Composition capable of reducing fat and supplying nutrients and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104825702A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105901269A (en) * | 2016-04-28 | 2016-08-31 | 张雅萍 | Konjac tablet candy for weight management and preparation method of konjac tablet candy for weight management |
| CN113729101A (en) * | 2021-08-17 | 2021-12-03 | 云南省农业科学院生物技术与种质资源研究所 | White-meat ganoderma-konjac glucomannan tablet candy and preparation method thereof |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2007295906A (en) * | 2006-04-27 | 2007-11-15 | Kenko No Eki:Kk | Devil's tongue powder |
| CN102648747A (en) * | 2011-02-25 | 2012-08-29 | 上海天龙药业有限公司 | Composition with fat-reducing function and preparation method of same |
-
2015
- 2015-05-07 CN CN201510228700.0A patent/CN104825702A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2007295906A (en) * | 2006-04-27 | 2007-11-15 | Kenko No Eki:Kk | Devil's tongue powder |
| CN102648747A (en) * | 2011-02-25 | 2012-08-29 | 上海天龙药业有限公司 | Composition with fat-reducing function and preparation method of same |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105901269A (en) * | 2016-04-28 | 2016-08-31 | 张雅萍 | Konjac tablet candy for weight management and preparation method of konjac tablet candy for weight management |
| CN113729101A (en) * | 2021-08-17 | 2021-12-03 | 云南省农业科学院生物技术与种质资源研究所 | White-meat ganoderma-konjac glucomannan tablet candy and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103735838B (en) | One breeding kidney health care medicinal liquor for tonifying kidney and preparation method thereof | |
| CN104126808B (en) | A kind of slimming health food and preparation method thereof | |
| CN101579120A (en) | Nutritional food with weight-losing function and preparation method thereof | |
| CN102090563B (en) | Relaxing and sleeping health-care food and preparation method thereof | |
| CN103285145A (en) | Pure traditional Chinese medicine preparation for prompting rapid growth of pigs as well as preparation method and application method thereof | |
| CN104825702A (en) | Composition capable of reducing fat and supplying nutrients and preparation method thereof | |
| CN106465946A (en) | A kind of loosening bowel to relieve constipation dietary fiber | |
| CN103156865B (en) | L-arabinose is preparing the application in medicine or health product | |
| CN104688970A (en) | Drug combination particles having function of losing weight and preparation method thereof | |
| CN105663900B (en) | Medicated diet for improving liver cirrhosis nutrition state | |
| CN104721428A (en) | Slimming composite granules and preparing method thereof | |
| CN108324874B (en) | Tea substitute for treating gouty arthritis with syndrome of intermingled cold and heat | |
| CN103181557A (en) | Nutritious food with slimming function and preparation method thereof | |
| CN101869329B (en) | Life-prolonging cancer-prevention healthcare beverage | |
| Ajagun-Ogunleye et al. | Hypoglycemic and high dosage effects of bidens pilosa in type-1 diabetes mellitus | |
| WO2013166858A1 (en) | Amorphophallus konjac healthcare and laxative capsule and preparation method therefor | |
| WO2013166859A1 (en) | Amorphophallus konjac healthcare and consumptive thirst capsule and preparation method therefor | |
| CN108477607A (en) | A kind of nutraceutical improving children and infantal sleeping | |
| CN100546598C (en) | A kind of oral liquid of eliminating hydrops and promoting graft function | |
| CN100387245C (en) | Medicine for treating erection dysfunction and preparation method thereof | |
| CN106387363A (en) | Iodine-enriched selenium-enriched chromium-enriched strengthening agent for eggs, as well as preparation method and use method of iodine-enriched selenium-enriched chromium-enriched strengthening agent | |
| CN103876207A (en) | Healthcare soup for treating postoperative constipation of cancer patients and preparation method thereof | |
| CN101249133B (en) | Medicament for treating leukemia and manufacturing method | |
| CN104187244A (en) | High-protein composition powder and preparation method thereof | |
| CN101584793B (en) | Pure natural health-care four-Huai medicine |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |